By PPN News Staff
The FDA granted a new indication to remdesivir (Veklury, Gilead) for use in COVID-19 patients with severe renal impairment, including those on dialysis.
With this approval, remdesivir is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. About 37 million people in the United States are estimated to have chronic kidney disease (CKD) and at increased risk for morbidity and mortality related to COVID-19.